Enzalutamide vs. Abiraterone in Chemotherapy-naïve Metastatic Castration-resistant Prostate Cancer (mCRPC)

Inclusion Criteria

• •Male with ≥ 1 diagnosis claim for prostate cancer
• •Have documented secondary metastasis code on or after the initial prostate cancer diagnosis
• •Have initiated enzalutamide or abiraterone within 90 days prior to the metastasis date or on or after the metastasis date. The initiation date of enzalutamide or abiraterone will be defined as the index date.
• •Have evidence of surgical or medical castration before the index date
• •At least 18 years old at the index date
• •Continuous eligibility for ≥ 12 months prior to the index date